IL306050A - Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties - Google Patents
Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological propertiesInfo
- Publication number
- IL306050A IL306050A IL306050A IL30605023A IL306050A IL 306050 A IL306050 A IL 306050A IL 306050 A IL306050 A IL 306050A IL 30605023 A IL30605023 A IL 30605023A IL 306050 A IL306050 A IL 306050A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- ring atoms
- group
- alkenyl
- heteroatom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167915P | 2021-03-30 | 2021-03-30 | |
| EP21305405 | 2021-03-30 | ||
| PCT/EP2022/058402 WO2022207699A1 (en) | 2021-03-30 | 2022-03-30 | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL306050A true IL306050A (en) | 2023-11-01 |
Family
ID=81580241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL306050A IL306050A (en) | 2021-03-30 | 2022-03-30 | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties |
Country Status (10)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| MX2024008640A (es) * | 2022-01-12 | 2024-07-24 | Regeneron Pharma | Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso. |
| AU2023231442B2 (en) * | 2022-03-11 | 2026-07-02 | Mablink Bioscience | Antibody-drug conjugates and their uses |
| JP2026504840A (ja) * | 2023-01-11 | 2026-02-10 | ジェンマブ エー/エス | リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法 |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| EP4512427A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| FR3155708A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| FR3155709A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025230926A1 (en) * | 2024-04-29 | 2025-11-06 | Obi Pharma, Inc. | Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof |
| WO2026076215A1 (en) * | 2024-10-03 | 2026-04-09 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2026085106A1 (en) * | 2024-10-15 | 2026-04-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2026086855A1 (zh) * | 2024-10-25 | 2026-04-30 | 石药集团巨石生物制药有限公司 | 一种靶向cdcp1的抗体药物偶联物及其用途 |
| WO2026112064A1 (en) * | 2024-11-20 | 2026-05-28 | Solve Therapeutics, Inc. | Conjugates of anti-5t4 antibodies with drugs and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775976B1 (fr) * | 1998-03-10 | 2000-06-02 | Fabre Pierre Dermo Cosmetique | Composition pharmaceutique ou cosmetique contenant un precurseur d'actif hydrolysable par la glucocerebrosidase |
| FR2960153B1 (fr) | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
| CN107847605B (zh) | 2015-11-25 | 2021-12-24 | 乐高化学生物科学股份有限公司 | 包含分支接头的抗体-药物缀合物及其相关方法 |
| EP3700577A1 (en) * | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
-
2022
- 2022-03-30 MX MX2023011630A patent/MX2023011630A/es unknown
- 2022-03-30 US US18/285,175 patent/US20240216525A1/en active Pending
- 2022-03-30 EP EP22720929.3A patent/EP4313157A1/en active Pending
- 2022-03-30 JP JP2023559766A patent/JP2024512986A/ja active Pending
- 2022-03-30 WO PCT/EP2022/058402 patent/WO2022207699A1/en not_active Ceased
- 2022-03-30 AU AU2022248565A patent/AU2022248565A1/en active Pending
- 2022-03-30 KR KR1020237037385A patent/KR20230165288A/ko active Pending
- 2022-03-30 BR BR112023019495A patent/BR112023019495A2/pt unknown
- 2022-03-30 IL IL306050A patent/IL306050A/en unknown
- 2022-03-30 CA CA3215279A patent/CA3215279A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023019495A2 (pt) | 2023-11-07 |
| WO2022207699A1 (en) | 2022-10-06 |
| KR20230165288A (ko) | 2023-12-05 |
| JP2024512986A (ja) | 2024-03-21 |
| MX2023011630A (es) | 2024-01-24 |
| US20240216525A1 (en) | 2024-07-04 |
| AU2022248565A1 (en) | 2023-10-05 |
| EP4313157A1 (en) | 2024-02-07 |
| CA3215279A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2678037T3 (en) | Branched linker for protein pharmaceutical conjugates | |
| JP2024512986A5 (cg-RX-API-DMAC10.html) | ||
| JP5557746B2 (ja) | 生体適合性生分解性フマギリンアナログ複合体 | |
| US6355673B1 (en) | Substituted diaminocarboxylic acids | |
| AU2017237186B2 (en) | Process for the preparation of PEGylated drug-linkers and intermediates thereof | |
| US6987092B1 (en) | Indigoid bisindole derivatives | |
| CN118652192A (zh) | 用于抗体药物缀合物的接头 | |
| WO2016014522A1 (en) | Inhibitors of deubiquitinating proteases | |
| ES2635117T3 (es) | Método para la fabricación de un copolímero de bloques | |
| JP2007535474A (ja) | 複合補体カスケードインヒビター | |
| WO2007018431A2 (en) | Triazole-containing releasable linkers and conjugates comprising the same | |
| NZ207992A (en) | Vinblastine conjugates and pharmaceutical compositions | |
| NO320322B1 (no) | Forbindelse, fremgangsmate for fremstilling av denne, legemiddel og farmasoytisk preparat inneholdende denne, anvendelse av forbindelsen og fremgangsmate for fremstilling av et legemiddel. | |
| WO2022045212A1 (ja) | トリスルフィド化合物及びその包接体 | |
| US20170360940A1 (en) | Nucleophile-triggered degradable materials and methods of making and using the same | |
| US20240042052A1 (en) | Process for the preparation of drug linker compounds | |
| WO2019047941A1 (zh) | 鹅膏毒肽类抗体偶联物 | |
| IE52767B1 (en) | Antibiotic derivatives, derived from cephalosporins | |
| CN110092902A (zh) | 一种丹参酮ⅱa高分子化合物及其制备和应用 | |
| CA3219550A1 (en) | Antibody drug conjugates using mates technology for delivering cytotoxic agents | |
| US10753942B2 (en) | Methods to detect remnant cancer cells | |
| CN120390747A (zh) | 用于靶向递送应用的碳酸酐酶ix配体 | |
| UA128730C2 (uk) | Альтернативні способи одержання тубулізинів та їх проміжних сполук | |
| CA2249747A1 (en) | Novel tripeptide compounds and anti-aids drugs | |
| ES2719796T3 (es) | Derivado de N-acilo O-aminofenol CBI cíclico |